医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mitsubishi Electric to Install Proton Beam Therapy System at New Cancer Treatment Clinic in Osaka, Japan

2013年10月09日 AM11:25
このエントリーをはてなブックマークに追加


 

TOKYO

Mitsubishi Electric Corporation (TOKYO:6503) announced today that it will provide its innovative proton beam therapy system for cancer treatment to the Hakuhokai Group healthcare organization led by Chairman Motohisa Kojo in Osaka, Japan. The system will be installed at the Hakuhokai Group Osaka Proton Therapy Clinic scheduled to open in April 2016.

The new system will feature a compact, single-room design that meets the growing global demand for more cost-effective proton therapy solutions. Mitsubishi Electric’s decades of experience in particle therapy systems will contribute to the increased availability of innovative, efficient systems in hospitals worldwide.

Proton Beam Therapy System

Mitsubishi Electric’s proton beam therapy system features the Universal Nozzle for operational efficiency and the high-dose-rate irradiation that can reduce the irradiation time. To obtain Japanese government approval of the new system in a timely manner, testing is now being performed at the Accelerator Test Facility in Mitsubishi Electric’s Kobe factory. Mitsubishi Electric will provide staff training and commissioning support to facilitate the early startup of treatment.

To date, eight of the 11 facilities now conducting particle therapy in Japan are using systems delivered by Mitsubishi Electric. More than 16,000 patients have so far been treated at these facilities. The Hakuhokai Group order, which was preceded by a separate order two weeks earlier from Tsuyama Chuo Hospital in Okayama, Japan, will become the tenth installation of a Mitsubishi Electric particle therapy system.

 
Facility   Prefecture   Year   Ion Species
National Institute of Radiological Sciences

(Main contractor: Mitsubishi Electric)

Chiba 1994 carbon
Hyogo Ion Beam Medical Center Hyogo 2001 proton/carbon
Shizuoka Cancer Center Shizuoka 2003 proton
Southern Tohoku Proton Therapy Center Fukushima 2008 proton
Gunma University Heavy Ion Medical Center Gunma 2010 carbon
Fukui Prefectural Hospital Proton Beam Cancer Treatment Center Fukui 2011 proton
Medipolis Medical Research Institute Kagoshima 2011 proton
Saga Heavy Ion Medical Accelerator in Tosu Saga 2013 carbon
Okayama University/Tsuyama Chuo Hospital Proton Beam Cancer Center Okayama 2016

(scheduled)

proton
Hakuhokai Group Osaka Proton Therapy Clinic   Osaka   2016

(scheduled)

  proton
 

About Mitsubishi Electric

With over 90 years of experience in providing reliable, high-quality products, Mitsubishi Electric Corporation (TOKYO:6503) is a recognized world leader in the manufacture, marketing and sales of electrical and electronic equipment used in information processing and communications, space development and satellite communications, consumer electronics, industrial technology, energy, transportation and building equipment. Embracing the spirit of its corporate statement, Changes for the Better, and its environmental statement, Eco Changes, Mitsubishi Electric endeavors to be a global, leading green company, enriching society with technology. The company recorded consolidated group sales of 3,567.1 billion yen (US$ 37.9 billion*) in the fiscal year ended March 31, 2013. For more information visit http://www.MitsubishiElectric.com

*At an exchange rate of 94 yen to the US dollar, the rate given by the Tokyo Foreign Exchange Market on March 31, 2013

CONTACT

Mitsubishi Electric Corporation
Customer Inquiries
Advanced
Magnetic and Medical Systems Marketing Department
pmd.pt@pz.MitsubishiElectric.co.jp
http://www.MitsubishiElectric.com/products/public/particle/index.html
or
Media
Inquiries

Katsunobu Muroi, +81-3-3218-2346
Public
Relations Division
prd.gnews@nk.MitsuibishiElectric.co.jp
http://www.MitsubishiElectric.com/news/

同じカテゴリーの記事 

  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report
  • マシモ創業者兼最高経営責任者(CEO)のジョー・キアニがチリで開催される世界患者安全サミットでAIについて講演
  • Masimo创始人兼首席执行官Joe Kiani将在智利举行的全球患者安全峰会上谈论人工智能
  • Codone Biotech to Present Data on its Suppressor-tRNA Platform in Disease Models with Nonsense Mutations (Premature Termination Codons)